Clinical Trial Update: A Multicenter, Open Trial With Subcutaneous Immunotherapy (SCIT) in Patients With Rhinoconjunctivitis Sensitized to Parietaria Judaica [Phase 1]

View source ↗

Summary

Phase 1 multicenter open-label trial evaluating subcutaneous immunotherapy for rhinoconjunctivitis in Parietaria judaica-sensitized patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rhinoconjunctivitis

Drugs mentioned

• Parietaria judaica allergen extract SCIT (Parietaria judaica allergen extract)

Snippet

Sponsor: Roxall Medicina España S.A | Conditions: Rhinoconjunctivitis | Phase 1 | Status: COMPLETED